SCHEMBL1103269

SCHEMBL1103269

c1ccc(-c2cc3ccccc3cc2-c2c3ccccc3c(-c3cc4ccccc4cc3-c3ccccc3)c3c2cnc2ccccc23)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.42
▸ ESR2 Q92731 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ GPR3 P46089 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ACACA Q13085 2/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ PDGFRA P16234 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103406 0.96 ESR1 (0.44) ESR1ESR2KDM4EGPR3LMNA
SCHEMBL1103521 0.91 SMN1; SMN2 (0.40) ESR1ESR2KDM4EGPR3LMNA
SCHEMBL1103365 0.85 CDK4 (0.39) KDM4EGPR3LMNANPC1MAPT
SCHEMBL1103266 0.85 CDK4 (0.39) KDM4EGPR3LMNANPC1MAPT
SCHEMBL1103378 0.84 KDM4E (0.44) ESR1ESR2KDM4EGPR3LMNA
SCHEMBL1103250 0.84 KDM4E (0.49) KDM4EGPR3LMNANPC1MAPT
SCHEMBL1103565 0.83 MAPT (0.42) ESR1ESR2KDM4EGPR3LMNA
SCHEMBL1103560 0.83 TNF (0.43) ESR1ESR2KDM4EGPR3LMNA
SCHEMBL1103506 0.83 MET (0.43) ESR1ESR2KDM4EGPR3LMNA
SCHEMBL1103503 0.83 MET (0.41) ESR1ESR2KDM4EGPR3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ESR1 1038/4885ESR2 576/4885KDM4E 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback